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The anti-cancer drug paclitaxel (Taxol) alters micro-
tubule assembly and activates pro-apoptotic signaling
pathways. Previously, we and others found that pacli-
taxel activates endogenous JNK in tumor cells, and the
activation of JNK contributes to tumor cell apoptosis.
Here we find that paclitaxel activates the prosurvival
MEK/ERK pathway, which conversely may compromise
the efficacy of paclitaxel. Hence, a combination treat-
ment of paclitaxel and MEK inhibitors was pursued to
determine whether this treatment could lead to en-
hanced apoptosis. The inhibition of MEK/ERK with a
pharmacologic inhibitor, U0126, together with pacli-
taxel resulted in a dramatic enhancement of apoptosis
that is four times more than the additive value of the
two drugs alone. Enhanced apoptosis was verified by
the terminal transferase-mediated dUTP nick end label-
ing assay, by an enzyme-linked immunosorbent assay
for histone-associated DNA fragments, and by flow cyto-
metric analysis for DNA content. Specificity of the phar-
macologic inhibitor was confirmed by the use of (a) a
second MEK/ERK inhibitor and (b) a transdominant-
negative MEK. Enhanced apoptosis was verified in
breast, ovarian, and lung tumor cell lines, suggesting
this effect is not cell type-specific. This is the first report
of enhanced apoptosis detected in the presence of pacli-
taxel and MEK inhibition and suggests a new anticancer
strategy.
Paclitaxel is a promising frontline chemotherapy in the
treatment of patients with ovarian, breast, and nonsmall cell
lung carcinomas (1, 2). Paclitaxel is isolated from the bark of
the pacific yew (Taxus brevifolia) and functions by binding and
stabilizing microtubules (3). Binding of paclitaxel to microtu-
bules blocks normal cell cycle progression during the merger of
mitotic metaphase and anaphase. This prevents chromosome
segregation, leading to tumor cell death.
Combination therapy of paclitaxel and Herceptin, an anti-
Her2-neu antibody, has produced impressive responses among
breast cancer patients (4), although this combination is obvi-
ously limited to Her2-neu1 tumors. Combination therapy with
other drugs, preferably via a rational molecular basis that is
widely applicable to many tumor types, is essential for im-
proved cancer treatment. A combination of paclitaxel with re-
agents that activate additional apoptotic signals, or inhibit
survival signals, may provide a rational molecular basis for
novel chemotherapeutic strategies.
A rational molecular target is the ERK1 mitogen-activated
protein (MAP) kinase pathway that may serve as an opposing
force to Jun N-terminal kinase (JNK/SAPK). Previous reports
have shown that JNK/SAPK leads to cell death, while MEK
activation contributes to cell differentiation, proliferation, and
survival (5, 6). Activated Raf-1, a serine-threonine kinase, ini-
tiates the signaling cascade through MEK, which in turn phos-
phorylates a second serine-threonine kinase ERK. ERK phos-
phorylates additional kinases and specific transcription
factors, such as Elk-1 and c-Fos, which are important in cell
proliferation. However, the link between Raf-1 and ERK acti-
vation and paclitaxel-induced cell death is not straightforward.
Several studies have shown that at a low concentration of the
drug, paclitaxel-mediated apoptosis is attributed to activated
Raf-1 (7–9). The role of the downstream ERK MAP kinase in
paclitaxel-induced tumor apoptosis is also not entirely clear
(10–14).
In this report, we tested the combined effects of paclitaxel
and inhibitors of MEK1/2 kinase on tumor cell apoptosis. The
specificity of MEK1/2 inhibition was achieved by using two
different MEK inhibitors, and by the additional use of trans-
dominant-negative mutants, which inhibit MEK/ERK activa-
tion. The reasons for selecting MEK1/2 as the target are: (i)
MEK is activated in many tumors (15, 16); (ii) small molecule-
based MEK inhibitors are readily available, and a recent report
has described a novel MEK inhibitor that exhibited in vivo
efficacy in mice (17–19); and (iii) MEK is critical in transform-
ing cells, leading to tumor survival and proliferation (20, 21). In
the present study, we show that paclitaxel increases MEK1/2
activity. The combined treatment of paclitaxel plus MEK1/2
inhibition leads to enhanced cell death in breast, ovarian, and
lung tumor lines.
EXPERIMENTAL PROCEDURES
JNK Kinase Assay—Following 2 h of paclitaxel (Sigma) treatment,
cells were washed, harvested with lysis buffer, and centrifuged at 4 °C
(10). Endogenous JNK was immunoprecipitated with anti-JNK anti-
body (Santa Cruz Biotechnology) and protein A-agarose beads for 2 h at
4 °C. Immunoprecipitates were collected by centrifugation (2,500 rpm)
at 4 °C. Immunoprecipitated JNK was mixed with 5 mg of glutathione
S-transferase-c-Jun and 10 mCi of [g-32P]ATP and incubated for 30 min* This work was supported by National Institutes of Health Grants
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minal deoxynucleotidyl transferase; TUNEL, TdT-mediated dUTP nick
end-labeling; CMV, cytomegalovirus; PAGE, polyacrylamide gel elec-
trophoresis; ELISA, enzyme-linked immunosorbent assay.
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at 30 °C. The reactions were terminated with SDS sample buffer and
resolved on a 10% SDS-PAGE gel.
Immunoblot Analysis—H157 human lung carcinoma cells were se-
rum-starved for 16 h and treated simultaneously with the indicated
concentrations of paclitaxel with or without 10 mM U0126 (Promega).
After 15 min of treatment, cells were lysed in 13 PBS, 1% Trition
X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 1 mM
Na3VO4, 10 mM leupeptin, and 10 mM pepstatin at 4 °C. Cell lysates were
separated with SDS-PAGE gels, transferred to nitrocellulose mem-
branes, and subjected to immunoblot analysis with anti-ERK mono-
clonal antibody for phosphorylated ERK1/2 (Santa Cruz Biotechnology).
Cell Death ELISA—Manufacturer’s instructions were followed for
the Cell Death Detection ELISAPLUS (Roche Molecular Biochemicals).
Briefly, cells were plated at 5 3 103 cells/well in 96-well microtiter
plates for 24 h. The cells were treated for 20–24 h with the indicated
doses of paclitaxel and U0126. Following lysis, the samples were cen-
trifuged and 20 ml of the supernatant transferred to a streptavidin-
coated microtiter plate as described (10). Anti-histone biotin and anti-
DNA peroxidase antibodies were added to each well, and the plate was
incubated at room temperature for 2 h. After three washes with incu-
bation buffer, the peroxidase substrate was added to each well. Follow-
ing a 15-min incubation, the plates were read at 405 nm in a microplate
reader. The data in this report are expressed as -fold increase in optical
density as compared with control treated cells.
Cell Cycle Analysis—Adherent and detached cells were collected with
trypsin and centrifuged at 200 3 g. Cells were resuspended at 2 3 106
cells/ml in PBS and fixed in ice-cold 70% ethanol for 2 h. Fixed cells
were centrifuged at 200 3 g, and each sample resuspended in pro-
pidium iodide (PI) stain buffer (0.1% Triton X-100, 200 mg of DNase-free
RNase A, 20 mg of PI) in PBS for 30 min. After staining, samples were
analyzed using a FACScan (Becton Dickinson) and ModFit LT (Verity
Software).
TUNEL Assay—Cells were split at a density of 3 3 104 cells/well in
a four-well chamber slide (Lab-Tek). Following a 36-h incubation, the
cells were treated with 10 nM paclitaxel in the presence or absence of 10
mM U0126 for 20 h. Following treatment, the cells were washed twice
with PBS and fixed with 4% paraformaldehyde for 10 min. Cells were
washed twice more with PBS and permeabilized with 0.2% Triton X-100
for 5 min. After two more washes, each slide was covered with equili-
bration buffer (Roche Molecular Biochemicals) for 10 more min. The
buffer was then aspirated, and the slides were incubated with TdT
buffer at 37 °C for 1 h. The reaction was stopped with 23 SSC, and the
slides were viewed with an immunofluorescence microscope.
RESULTS AND DISCUSSION
The effect of paclitaxel on JNK and ERK activities is shown
in Fig. 1. Basal JNK activity was detected, and this activity
was significantly enhanced by treatment with low, nanomolar
doses of paclitaxel in human lung and breast carcinoma cell
lines (Fig. 1A). A basal level of ERK was also detected, and low
doses of paclitaxel activated endogenous ERK1 and ERK2 (Fig.
1B). The MEK inhibitor, U0126, completely blocked ERK acti-
vation by paclitaxel. The activation of JNK in this scenario has
been previously found to contribute to apoptosis, while the role
of paclitaxel-induced ERK has not been studied. In other sys-
tems, ERK generally plays a critical role in cell proliferation
and growth (22); thus, it was reasoned that ERK activation by
paclitaxel might enhance cell proliferation and compromise the
efficacy of this drug. A logical approach is to use pharmacologic
blockers of MEK to inhibit paclitaxel-induced ERK activation
and its downstream effects.
To test this hypothesis, a combination of paclitaxel and a
potent MEK1 inhibitor, U0126, was used to treat a variety of
human carcinoma lines, and cell death was measured by the
cell death detection ELISA that detects DNA-histone fragmen-
tation. The combination of paclitaxel plus U0126 enhanced cell
death (Fig. 2A). The -fold increase in apoptosis was calculated
by comparing the ELISA optical density readings of treated
samples, with the value of the untreated control as 1.0. In H157
cells, paclitaxel and U0126 combined caused four times more
cell death than paclitaxel alone, and eight times more cell
death than U0126 alone. A similar trend was observed in
OVCA194 cells.
The potential use of low dose chemotherapy is important,
because lower dosages are more attainable during cancer ther-
apy and likely to cause less toxicity in patients. We performed
a dose-response analysis to assess the minimal concentration of
paclitaxel, which when combined with U0126, causes enhanced
cell death. Low doses of paclitaxel, starting at the 10 nM range,
combined with U0126 cause enhanced cell death in both BT474
breast and H157 lung carcinoma cells (Fig. 2B).
To control for pharmacologic specificity, two additional ex-
periments were performed. First, a second MEK inhibitor
PD98059 was used and produced similar data (Fig. 2C), pro-
viding additional evidence that the MEK enzyme is the target.
However, pharmacologic approaches have their limitations, be-
cause the specificity of the drug can always be questioned. To
provide further evidence for the effects of MEK inhibition, a
dominant-negative MEK (dnMEK) mutant was introduced into
H157 cells. Expression of dnMEK in the presence of low dose
(50 and 250 nM) paclitaxel enhanced apoptosis over the pCMV
empty vector control (Fig. 2D).
Table I summarizes enhanced apoptosis observed with pacli-
taxel and U0126. In H157 and OVCA194 cells, the combination
treatment produced 4.0- and 2.5-fold enhancement of apoptosis
over the expected additive effect. This enhancement was
achieved with relative low dosages (1 mM paclitaxel, 10 mM
U0126) of these two drugs. This trend was also observed with
the breast carcinoma BT474 (not shown).
To examine the mechanism of U0126 and paclitaxel induced
cell death, their effects on cell cycle progression was studied.
The BT474 breast carcinoma cells were treated with paclitaxel
and/or U0126, and cell cycle progression was analyzed by in-
cubating the cells with propidium iodide, which allowed the
analysis of DNA content by flow cytometry. U0126 arrested
BT474 cells in G1, while 10 nM paclitaxel produced a dramatic
G2 block (Fig. 3A). The percentage of control treated cells in
G2-M was 13%, which increased to 75% after treatment with 10
nM paclitaxel for 24 h. Seventeen percentage of the cells under-
went apoptosis in the presence of paclitaxel, while a negligible
increase in cell death was detected in the presence of U0126
FIG. 1. Effects of paclitaxel and MEK inhibitor on MAP ki-
nases. A, paclitaxel-activated endogenous JNK. Human breast (BT474)
and lung (H358) carcinoma cell lines were treated with the indicated
concentrations of paclitaxel for 2 h, and JNK kinase activity was as-
sayed as described under “Experimental Procedures.” B, paclitaxel-
activated endogenous ERK and activation is reversed by U0126. H157,
a human lung carcinoma, and BT474 cells were serum-starved for 16 h
and treated with the indicated concentrations of paclitaxel for 15 min.
Cell lysates were subjected to immunoblot analysis with anti-ERK
antibody for phosphorylated ERK1/2. The MEK inhibitor U0126
blocked ERK activation by paclitaxel (lower panel). H157 cells were
serum-starved for 16 h and treated simultaneously with paclitaxel with
and without 10 mM U0126 for 15 min.
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when compared with the control (6% compared with 4%). In
contrast, the combination of paclitaxel and U0126 substan-
tially increased cell death as evidence by accumulation of a
sub-G1 population that has ,2 N DNA (Fig. 3A) and represents
dead cells. These results further support the ELISA result that
low doses of paclitaxel and U0126 enhanced tumor cell death.
To assess if the cell death observed above represents apo-
ptosis, a TUNEL assay was performed with paclitaxel, U0126,
or a combination of the two drugs. Singly, paclitaxel and U0126
caused little apoptosis (0.6 and 0.4%, see panels i–vi, Fig. 3B) as
measured by the number of TUNEL-positive cells. When cells
were treated with both, there was a dramatic increase in the
number of TUNEL-positive cells to 11.1% (panels vii and viii,
Fig. 3B). Phase-contrast photomicrographs of H157 cells re-
vealed changes in morphology and cell membrane blebbing,
which are characteristics of apoptosis (panel ix, Fig. 3B). These
results further indicate that paclitaxel and U0126 enhance
apoptosis.
In the last 2 years, we and others have reported that pacli-
taxel affects MAP kinases. The best documented is the activa-
tion of JNK/SAPK by paclitaxel, which has been found in a
variety of tumor cell lines (10–13). JNK/SAPK activation is
primarily a stress response, long proposed to be a determining
factor in cell cycle arrest and apoptosis (23). Studies of hip-
pocampal neuronal cells show that these cells do not undergo
apoptosis when a JNK subgroup (jnk1, jnk2, or jnk3) is mu-
tated. Very recently, the use of mice lacking functional JNK
provides strong evidence that JNK is important in causing
apoptosis (24–26). Most relevant to this present study, JNK
activation by paclitaxel directly contributes to apoptosis, as
transdominant-negative JNK/SAPK significantly blocked pa-
clitaxel-induced cell death (10–13).
Extensive research has identified potential mechanisms of
paclitaxel-induced cell death, most prominent is the effect on
BCL-2 family members and p53. Several reports indicate that
paclitaxel causes the phosphorylation and inactivation of
BCL-2 and its family members (7, 9, 27–29), while other stud-
ies have found paclitaxel sensitivity varies with p53 status
(30–32). Additionally, a link between JNK and BCL-2 was
found, where JNK mediated BCL-2 phosphorylation, and the
inactivation of JNK inhibited paclitaxel-induced BCL-2 phos-
phorylation (33). This establishes the important roles of BCL-2
and JNK family members in paclitaxel-induced apoptosis, al-
though other cell death and cell survival pathways are likely to
either enhance or intercede with this cytotoxicity. One of the
findings described here is that paclitaxel also enhances the
activation of the MEK/ERK pathway, which is expected to
increase cell proliferation and survival, and may compromise
the efficacy of paclitaxel in cancer treatment.
Based on a molecular approach, this report describes a novel
discovery that treatment with paclitaxel combined with the
inhibition of MEK1/2 lead to enhanced apoptosis of lung, ovar-
ian, and breast carcinoma cell lines. Two pharmacologic agents,
paclitaxel and U0126, respectively, caused JNK activation that
promotes apoptosis, and MEK inhibition, which leads to cell
cycle arrest. The two combined resulted in an impressive en-
hancement of tumor cell killing.
In summary, these findings illustrate the power of molecular
and rational drug targeting. Paclitaxel and MEK inhibitor com-
bination therapy may allow the use of lower drug doses, likely
FIG. 2. Analysis of paclitaxel and MEK inhibitor on carcinoma
cell death. A, paclitaxel and U0126 caused enhanced carcinoma cell
death. H157 lung and OVCA194 ovarian carcinoma cells were treated
with 1 mM paclitaxel, 10 mM MEK inhibitor U0126, or a combination of
paclitaxel and MEK inhibitor. Twenty-four hours later, a cell death
ELISA that measures cell death by DNA-histone release was performed
as described under “Experimental Procedures.” B, low dose, nanomolar
range of paclitaxel and 10 mM U0126 caused enhanced killing. BT474
breast carcinoma and H157 lung carcinoma cells were treated with the
indicated concentrations of paclitaxel in the presence or absence of 10
mM U0126, and -fold increase in cell death was measured by ELISA. C,
a second MEK inhibitor, PD98059, and paclitaxel caused enhanced cell
death. H157 lung carcinoma cells were treated with either 10 mM U0126
or 50 mM PD98059 for 20 h and analyzed by the cell death ELISA. D,
dnMEK and paclitaxel caused enhanced cell death. H157 cells were
transfected with 100 ng of pCMV vector control or dnMEK (34). After
24 h, cells were treated with the indicated amount of paclitaxel for 24 h
and cell death assayed by ELISA.
TABLE I
Combination treatment with paclitaxel and MEK inhibitor U0126
H157 and OVCA194 cells were treated with the indicated concentra-
tions of U0126 and paclitaxel for 24 h. Apoptosis was analyzed by cell
death ELISA that measures DNA-histone release, and data are ex-





Combination treatment Fold increase
over additivebExpecteda Observed
H157 3.0 13.0 16.0 63.7 4.0
OVCA194 3.1 8.7 11.8 30.1 2.5
a (Mean cell death of U0126) 1 (mean cell death of paclitaxel).
b (Observed combination)/(expected combination).
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leading to lowered toxicity and enhanced tumor killing in vivo.
The implications of these findings are broad for the potential
clinical usage of paclitaxel plus MEK inhibitors by: 1) improv-
ing the response rate and 2) expanding the usefulness of pacli-
taxel in the treatment of resistant tumors that affects a large
percentage of cancer patients.
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FIG. 3. Paclitaxel and MEK inhibitor U0126 block cell cycle progression and cause enhanced cell death. A, BT474 breast carcinoma
cells were treated for 24 h before staining with propidium iodide and analyzed by flow cytometry as described under “Experimental Procedures.”
Histograms of control (Me2SO-treated) cells exhibited normal cell cycle progression. Ten mM U0126 induced G1 growth arrest, 10 nM paclitaxel
induced G2 growth arrest, and 10 nM paclitaxel plus 10 mM U0126 caused enhanced death by an accumulation of sub-G1 dead cells. The percentage
of cells in each phase of the cell cycle are shown below the histograms. B, paclitaxel and U0126 cause enhanced apoptosis. H157 cells were grown
on coverslips and treated with 10 nM paclitaxel and/or 10 mM U0126 as indicated. After 16 h, the slides were incubated and TUNEL stained. The
phase contrast photomicrographs (panels i, iii, v, and vii) and the corresponding immunofluorescence photomicrographs (panels ii, iv, vi, and viii)
of cells undergoing apoptosis are shown. The number in the lower right of each panel represents the percentage of TUNEL-positive cells.
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